Literature DB >> 27408341

Plasma concentrations of buprenorphine following a single subcutaneous administration of a sustained release formulation of buprenorphine in sheep.

Chiara Zullian1, Pablo Lema1, Melissa Lavoie1, Aurore Dodelet-Devillers1, Francis Beaudry1, Pascal Vachon1.   

Abstract

The goal of the present study was to evaluate the potential use of slow release buprenorphine in sheep. Twelve adult female sheep (6 Dorset and 6 Suffolk, 12 months of age) were used for this project and were divided into 2 experimental groups (n = 6/group comprising 3 Dorset and 3 Suffolk sheep). Sustained release (SR) buprenorphine was administered subcutaneously in the scapular region at a concentration of 0.1 mg/kg body weight (BW) for group 1 and of 0.05 mg/kg BW for group 2. Following blood collections at selected time points, plasma concentrations of buprenorphine was performed by tandem liquid chromatograph-mass spectrometry. Mean buprenorphine concentration was above 0.1 ng/mL at 48 h up to 192 h post-injection for group 1 and it was above 0.1 ng/mL at 48 h up to 72 h post-injection for group 2. In conclusion, a long lasting potential analgesic plasma level of buprenorphine is attained following a single subcutaneous injection of 0.1 mg/kg BW of SR buprenorphine in sheep. However the effective analgesic plasma threshold still needs to be determined in sheep.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27408341      PMCID: PMC4924562     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  18 in total

1.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Authors:  P Huang; G B Kehner; A Cowan; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

2.  Accidental prehension and suspected transmucosal or oral absorption of fentanyl from a transdermal patch in a dog.

Authors:  Chad W Schmiedt; Dale E Bjorling
Journal:  Vet Anaesth Analg       Date:  2007-01       Impact factor: 1.648

3.  P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception.

Authors:  Sarah M Brown; Scott D Campbell; Amanda Crafford; Karen J Regina; Michael J Holtzman; Evan D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  2012-06-27       Impact factor: 4.030

4.  Antinociceptive effects of sustained-release buprenorphine in a model of incisional pain in rats (Rattus norvegicus).

Authors:  Helen H Chum; Katechan Jampachairsri; Gabriel P McKeon; David C Yeomans; Cholawat Pacharinsak; Stephen A Felt
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-03       Impact factor: 1.232

5.  Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Authors:  Sarah M Brown; Michael Holtzman; Thomas Kim; Evan D Kharasch
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

6.  Comparison of the efficacy and adverse effects of sustained-release buprenorphine hydrochloride following subcutaneous administration and buprenorphine hydrochloride following oral transmucosal administration in cats undergoing ovariohysterectomy.

Authors:  Davina L Catbagan; Jessica M Quimby; Khursheed R Mama; Jessica K Rychel; Patrice M Mich
Journal:  Am J Vet Res       Date:  2011-04       Impact factor: 1.156

7.  Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats.

Authors:  Patricia L Foley; Haixiang Liang; Andrew R Crichlow
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-03       Impact factor: 1.232

8.  Pharmacokinetics of sustained-release and transdermal buprenorphine in Göttingen minipigs (Sus scrofa domestica).

Authors:  Allison J Thiede; Kelly D Garcia; DeAnne F Stolarik; Junli Ma; Gary J Jenkins; Elizabeth A Nunamaker
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-11       Impact factor: 1.232

Review 9.  Buprenorphine: a reappraisal of its antinociceptive effects and therapeutic use in alleviating post-operative pain in animals.

Authors:  J V Roughan; P A Flecknell
Journal:  Lab Anim       Date:  2002-07       Impact factor: 2.471

10.  The effect of transdermal delivery of fentanyl on activity in growing pigs.

Authors:  L M Malavasi; H Augustsson; M Jensen-Waern; G Nyman
Journal:  Acta Vet Scand       Date:  2005       Impact factor: 1.695

View more
  2 in total

1.  Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use.

Authors:  Viktoria Schreiner; Mattea Durst; Margarete Arras; Pascal Detampel; Paulin Jirkof; Jörg Huwyler
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

Review 2.  Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection.

Authors:  Henriikka Hakomäki; Hannu Kokki; Marko Lehtonen; Veli-Pekka Ranta; Juha Räsänen; Hanna-Marja Voipio; Merja Kokki
Journal:  Pharmacol Res Perspect       Date:  2021-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.